Biotech Values

[DewDiligence]

CRIS caveat emptor—(n=7):

https://www.prnewswire.com/news-releases/curis-announces-positive-preliminary-data-from-ongoing-phase-1-study-of-ca-4948-monotherapy-in-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-and-myelodysplastic-syndromes-301188059.html

As of November 23, 2020, 4 AML patients and 3 high-risk MDS patients had been enrolled in the first 2 study cohorts and no DLTs had been observed. The data being reported from this ongoing trial are preliminary and subject to change.

Emphasis added.